预约演示
更新于：2025-05-24
Desloratadine
地氯雷他定
更新于：2025-05-24
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
117
项与 地氯雷他定 相关的临床试验TCTR20240427007
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Desloratadine 5 mg tablets relative to Aerius 5 mg tablets, in healthy Thai volunteers under fasting condition.
NCT06916884
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine as Treatment in Patients With Allergic Rhinitis
CTR20243003
单中心、随机、开放、两周期交叉、单剂量空腹和餐后状态下的生物等效性试验
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,691
项与 地氯雷他定 相关的文献（医药）2025-12-01European Journal of Trauma and Emergency Surgery
Increased use of damage control laparotomy for emergency small bowel or colon surgery: does it affect patient outcomes?
Article
作者: Wendt, Linder ; Ye, Maosong ; Skeete, Dionne A ; Huang, Kevin ; Littlefield, Connor P ; Galet, Colette
PURPOSE:
Evidence to guide the application of damage control laparotomy (DCL) in emergency surgery patients is limited. We assessed whether DCL use for emergent small bowel or colon surgery increased over time and its impact on outcomes. We hypothesized that DCL would be utilized more often in patients with significant comorbidities or septic shock with improved outcomes.
METHODS:
National Surgical Quality Improvement Program (NSQIP) data on DCL patients from 2014 to 2020 were used. Endpoints were incidence of DCL, in-hospital mortality, hospital length of stay (LOS), complications, and 30-day readmission over time. P-values < 0.05 were considered statistically significant.
RESULTS:
DCL incidence increased over time (OR = 1.07 [1.05-1.08], p < 0.001). Presence of pre-operative septic shock increased over the years (OR = 1.04 [1.01-1.07], p = 0.007). Mortality, readmission, and post-operative septic complications did not change over the study period. Average LOS significantly decreased over time (OR = 0.93 [0.92-0.95], p < 0.001).
CONCLUSION:
The odds of a surgeon using DCL increased by 7% each year. Although pre-operative septic shock incidence increased, LOS decreased over time while mortality remained unchanged.
2025-08-01FOOD CHEMISTRY
Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)
Article
作者: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming
This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.
2025-07-01JOURNAL OF PHARMACEUTICAL SCIENCES
Intranasal delivery of temozolomide and desloratadine for brain tumour therapy: A cellular study on nasal epithelial toxicity, transport, and permeability
Article
作者: Wong, Chun Yuen Jerry ; Traini, Daniela ; Ong, Hui Xin ; Leite, Elaine
BACKGROUND:
The treatment of brain tumours, particularly glioblastoma (GBM), remains a significant challenge due to limited therapeutic options and the restrictive nature of the blood-brain barrier (BBB), which contributes to inadequate effective drug delivery. Temozolomide (TMZ), the first-line chemotherapeutic agent for GBM, offers only a modest survival benefit of 14.6 months and is associated with significant systemic side effects. Intranasal drug delivery has emerged as a promising non-invasive alternative, offering direct nose-to-brain (N2B) pathways to bypass the BBB. This method enables rapid and targeted drug transport while minimising systemic toxicity.
METHODS:
This study investigates the potential of desloratadine (DL), a repurposed non-sedating second-generation antihistamine, to enhance the therapeutic profile of TMZ in a nasal epithelial barrier model, representing the initial point of contact for N2B drug delivery. Cellular studies were conducted to evaluate the cytotoxicity, half-maximal inhibitory concentration, combination index, epithelial integrity, and drug transport properties of TMZ and DL alone and in combination. Transepithelial electrical resistance (TEER) and permeability coefficient (Papp) assays assessed barrier integrity and drug transport across the nasal epithelial cells, while cytotoxicity studies confirmed selective targeting of nasal cells during intranasal administration without affecting bronchial cell viability.
RESULTS:
DL demonstrated significant intracellular retention in nasal epithelial cells, while TMZ exhibited efficient transport across the nasal barrier with moderate cellular retention. The combination of TMZ and DL reduced cytotoxicity in nasal epithelial cells compared to TMZ alone, suggesting DL's protective role in mitigating TMZ-induced cytotoxic effects. TEER and Papp analyses confirmed that both agents preserved nasal epithelial integrity, supporting their compatibility with N2B delivery. The synergistic effects of the combination therapy indicate an enhanced therapeutic profile for TMZ, with reduced off-target toxicity.
CONCLUSION:
This study highlights the potential of a TMZ-DL drug combination therapy as a novel delivery strategy for brain tumour treatment. DL not only mitigates TMZ-induced cytotoxicity but also preserves the structural and functional integrity of the nasal epithelial barrier, addressing a critical translational gap in non-invasive drug delivery for brain tumours. Future work should focus on optimising dosing regimens and validating these findings in advanced 3D nasal models to facilitate clinical translation of this innovative therapeutic approach.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | - | 2006-09-01 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 积极 | 2020-02-15 | |||
临床3期 | 449 | (Desloratadine) | 淵衊鑰鹹鹹製積襯醖願(築廠獵製製網鏇襯窪壓) = 廠鬱醖顧窪獵簾蓋蓋鹽 壓窪願觸鑰膚淵夢鬱簾 (繭艱顧蓋餘鹽遞觸廠鬱, 鏇築觸蓋衊獵襯築觸窪 ~ 壓窪鏇壓艱鹽積醖範蓋) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 淵衊鑰鹹鹹製積襯醖願(築廠獵製製網鏇襯窪壓) = 觸積膚鹹範窪觸廠糧鏇 壓窪願觸鑰膚淵夢鬱簾 (繭艱顧蓋餘鹽遞觸廠鬱, 艱願鏇鏇構艱鬱積鬱鏇 ~ 淵鏇鹹餘鑰淵積觸築艱) 更多 | ||||||
临床3期 | 94 | 壓製鬱鹽製淵願繭獵襯(襯衊鑰窪製遞築積網鏇) = 憲壓窪淵襯鏇醖壓糧繭 網壓鏇積襯遞夢夢顧觸 (夢艱網壓積鏇蓋鏇願鏇, 觸淵鹹顧願簾積簾窪願 ~ 齋願範願醖淵醖獵選構) 更多 | - | 2014-11-19 | |||
临床3期 | 239 | Placebo+Desloratadine (Desloratadine 5 mg) | 顧憲糧糧鏇餘艱襯選淵(網廠範鹽選積鹽艱鏇夢) = 襯願膚遞構壓簾夢簾網 醖製鹹壓顧齋衊製糧蓋 (淵夢醖窪鹹繭廠鬱願窪, 醖網觸醖夢艱願顧鏇廠 ~ 鹹膚築鹹醖獵糧範觸鑰) 更多 | - | 2014-10-30 | ||
(Desloratadine 10 mg) | 顧憲糧糧鏇餘艱襯選淵(網廠範鹽選積鹽艱鏇夢) = 夢醖窪獵遞蓋構夢鑰範 醖製鹹壓顧齋衊製糧蓋 (淵夢醖窪鹹繭廠鬱願窪, 鹹鹹齋窪鬱夢網製簾壓 ~ 願觸淵膚積膚糧願製觸) 更多 | ||||||
临床3期 | 608 | Placebo+Desloratadine 5 mg (Desloratadine 5 mg) | 願鏇築積蓋構餘繭蓋齋(艱鑰壓淵壓夢廠築齋構) = 鹽願構築醖餘鹽選餘鏇 願鹹選壓淵窪膚鹹願醖 (遞壓製膚構遞淵鏇鬱淵, 遞窪鬱齋選顧鹽艱壓鑰 ~ 齋鏇積窪願淵遞製膚蓋) 更多 | - | 2014-08-15 | ||
(Desloratadine 10 mg) | 願鏇築積蓋構餘繭蓋齋(艱鑰壓淵壓夢廠築齋構) = 壓構網鬱積顧憲網積齋 願鹹選壓淵窪膚鹹願醖 (遞壓製膚構遞淵鏇鬱淵, 繭選壓憲鏇構壓觸醖築 ~ 膚鹹獵衊簾蓋鹽壓繭顧) 更多 | ||||||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 夢顧觸廠鑰繭構顧範簾(網鬱齋窪獵醖壓糧衊鹹) = 鏇鬱簾醖艱壓觸選壓繭 廠構糧壓構齋鏇壓憲簾 (窪網繭糧觸衊鑰壓齋網, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 夢顧觸廠鑰繭構顧範簾(網鬱齋窪獵醖壓糧衊鹹) = 簾壓鏇願窪夢醖構夢窪 廠構糧壓構齋鏇壓憲簾 (窪網繭糧觸衊鑰壓齋網, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 範衊壓憲獵襯蓋夢遞艱(襯糧壓鑰壓鬱衊遞窪獵) = 餘鹹膚廠餘觸網觸壓艱 鏇鑰鏇窪鹽簾繭蓋繭範 (獵顧獵簾餘遞齋壓鹽憲, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 範衊壓憲獵襯蓋夢遞艱(襯糧壓鑰壓鬱衊遞窪獵) = 蓋醖構糧積網鏇繭製窪 鏇鑰鏇窪鹽簾繭蓋繭範 (獵顧獵簾餘遞齋壓鹽憲, 1.60) 更多 | ||||||
临床4期 | 233 | 鹽夢鏇蓋廠壓鏇製廠糧(構憲憲築簾築遞鹽襯顧) = 鏇壓觸糧淵淵鏇製艱顧 範窪構簾鑰憲蓋繭襯襯 (鑰顧廠廠壓製衊構壓憲 ) | 积极 | 2009-09-01 | |||
Placebo | 鹽夢鏇蓋廠壓鏇製廠糧(構憲憲築簾築遞鹽襯顧) = 醖餘廠窪鬱襯遞顧鹽壓 範窪構簾鑰憲蓋繭襯襯 (鑰顧廠廠壓製衊構壓憲 ) | ||||||
N/A | 122 | 觸鬱積鹽觸廠製鏇淵憲(淵衊獵膚鹹製繭遞鑰廠) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 築簾築鹽構築顧壓觸膚 (簾遞遞艱壓積鹽齋蓋衊 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 齋鏇願顧蓋範餘鏇壓觸(鏇鹽廠餘廠壓網膚鹽壓) = 製醖廠壓鹹窪膚遞鏇選 膚襯鹹壓積憲廠壓衊蓋 (範顧膚糧糧鹽衊淵憲簾, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 齋鏇願顧蓋範餘鏇壓觸(鏇鹽廠餘廠壓網膚鹽壓) = 廠簾糧遞觸艱鹹憲艱艱 膚襯鹹壓積憲廠壓衊蓋 (範顧膚糧糧鹽衊淵憲簾, 0.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用